PT  - JOURNAL ARTICLE
AU  - J Fernando Arevalo
AU  - Andres F Lasave
AU  - Lihteh Wu
AU  - Dhariana Acon
AU  - Michel E Farah
AU  - Roberto Gallego-Pinazo
AU  - Arturo A Alezzandrini
AU  - Veronica Fortuna
AU  - Hugo Quiroz-Mercado
AU  - Guillermo Salcedo-Villanueva
AU  - Mauricio Maia
AU  - Martin Serrano
AU  - Sergio Rojas
TI  - Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group
AID  - 10.1136/bjophthalmol-2015-307950
DP  - 2016 Dec 01
TA  - British Journal of Ophthalmology
PG  - 1605--1610
VI  - 100
IP  - 12
4099  - http://bjo.bmj.com/content/100/12/1605.short
4100  - http://bjo.bmj.com/content/100/12/1605.full
SO  - Br J Ophthalmol2016 Dec 01; 100
AB  - Background/aims To report the long-term anatomical and functional outcomes of patients with centre-involved diabetic macular oedema (DME) treated with intravitreal bevacizumab (IVB).Methods Retrospective case series. Patients diagnosed with centre-involved DME that were treated with at least one injection of 1.25 mg IVB and had a minimum follow-up of 60 months. Patients underwent measurement of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography and fluorescein angiography at baseline, 6-month, 12-month, 24-month, 36-month, 48-month and 60-month visits. The paired samples t test was used to compare the central macular thickness (CMT) and BCVA with baseline values. Statistical significance was indicated by p<0.05.Results Two hundred and one consecutive patients (296 eyes) were included. The mean number of IVB injections per eye was 8.4±7.1 (range: 1–47 injections). At 5 years, the BCVA remained stable at 20/100 (logarithm of the minimum angle of resolution=0.7±0.4). Eighty-six (29%) eyes improved ≥2 lines of BCVA, 129 (43.6%) eyes remained stable and 81 (27.4%) eyes lost ≥2 lines of BCVA at 60 months. Mean CMT decreased from 403.5±142.2 μm at baseline to 313.7±117.7 μm over 5 years follow-up (p≤0.0001).Conclusions The early visual gains due to IVB were not maintained 5 years after treatment.